Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

CORP trial - Summary & Results


Published on

A multicenter, double-blind randomized trial of colchicine on Colchicine for Recurrent Pericarditis (CORP) for secondary prevention of pericarditis.

Published in: Health & Medicine, Technology
  • Be the first to comment

  • Be the first to like this

CORP trial - Summary & Results

  1. 1. CORP (Colchicine for RecurrentPericarditis)
  2. 2. CORP (Colchicine for Recurrent Pericarditis) M Imazio (Vittoria Hospital, Turin, Italy) European Society of Cardiology 2011 Congress• A multicenter, double-blind randomized trial of colchicine for secondary prevention of pericarditis• Population and treatment: 120 patients with a first recurrence of pericarditis Randomized to placebo or low-dose colchicine (1 mg bid for 24 hours)a,b in addition to conventional treatment (aspirin 800–1000 mg or ibuprofen 600 mg every 8 hours for 7 to 10 days or prednisone 0.2–0.5 mg/kg/day for 4 weeks)b• Outcomes: Primary efficacy end point: Recurrence rate at 18 months Secondary end points: Symptom persistence at 72 hours, remission rate at one month, number of recurrences, time to subsequent recurrence, disease-related hospitalization, cardiac tamponade, and constrictive pericarditis a. An additional 0.5 mg bid for 6 months was given for those weighing >70 kg b. Aspirin or ibuprofen as first choice, prednisone as second choice
  3. 3. CORP: Results• Colchicine halved the rate of recurrence: 24% vs 55% for those taking colchicine vs those on placebo, respectively (relative risk reduction 56%; p<0.001)• There were also significant reductions in a number of secondary end points among those taking colchicine vs placebo• This translates into a number needed to treat of only three patients to prevent one recurrence
  4. 4. CORP: Commentary*"Colchicine appears to be a safe, low-cost drug for rapid symptom relief, improvedremission rates at one week, and reduced recurrence after an initial episode ofrecurrent pericarditis." - Dr Massimo Imazio"The time has come where colchicine should be more freely used." - Dr Andre Keren*All comments from CORP: Colchicine prevents recurrent pericarditis(
  5. 5. Become a member of Become a fan on Facebook: Follow us on Twitter: is the leading online source of independent cardiology news.We are the top provider of news and opinions for over 100 000 physicians.